269 related articles for article (PubMed ID: 29683475)
21. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
22. Interventions for preventing bone disease in kidney transplant recipients.
Palmer SC; McGregor DO; Strippoli GF
Cochrane Database Syst Rev; 2007 Jul; (3):CD005015. PubMed ID: 17636784
[TBL] [Abstract][Full Text] [Related]
23. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.
Israeli RS; Rosenberg SJ; Saltzstein DR; Gottesman JE; Goldstein HR; Hull GW; Tran DN; Warsi GM; Lacerna LV
Clin Genitourin Cancer; 2007 Mar; 5(4):271-7. PubMed ID: 17553207
[TBL] [Abstract][Full Text] [Related]
24. Bisphosphonate therapy for osteogenesis imperfecta.
Dwan K; Phillipi CA; Steiner RD; Basel D
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD005088. PubMed ID: 27760454
[TBL] [Abstract][Full Text] [Related]
25. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
26. RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients.
Kachnic LA; Pugh SL; Tai P; Smith M; Gore E; Shah AB; Martin AG; Kim HE; Nabid A; Lawton CA
Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):382-6. PubMed ID: 24080992
[TBL] [Abstract][Full Text] [Related]
27. Bisphosphonates for advanced prostate cancer.
Yuen KK; Shelley M; Sze WM; Wilt T; Mason MD
Cochrane Database Syst Rev; 2006 Oct; (4):CD006250. PubMed ID: 17054286
[TBL] [Abstract][Full Text] [Related]
28. Bisphosphonate therapy for osteogenesis imperfecta.
Dwan K; Phillipi CA; Steiner RD; Basel D
Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
[TBL] [Abstract][Full Text] [Related]
29. Rehabilitation following surgery for flexor tendon injuries of the hand.
Peters SE; Jha B; Ross M
Cochrane Database Syst Rev; 2021 Jan; 1(1):CD012479. PubMed ID: 33434949
[TBL] [Abstract][Full Text] [Related]
30. Vitamin D, calcium or a combination of vitamin D and calcium for the treatment of nutritional rickets in children.
Chibuzor MT; Graham-Kalio D; Osaji JO; Meremikwu MM
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012581. PubMed ID: 32303107
[TBL] [Abstract][Full Text] [Related]
31. Interventions for preventing osteoradionecrosis of the jaws in adults receiving head and neck radiotherapy.
El-Rabbany M; Duchnay M; Raziee HR; Zych M; Tenenbaum H; Shah PS; Azarpazhooh A
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31745986
[TBL] [Abstract][Full Text] [Related]
32. Internal fixation implants for intracapsular hip fractures in older adults.
Lewis SR; Macey R; Eardley WG; Dixon JR; Cook J; Griffin XL
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013409. PubMed ID: 33687067
[TBL] [Abstract][Full Text] [Related]
33. Nutritional interventions for survivors of childhood cancer.
Cohen JE; Wakefield CE; Cohn RJ
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD009678. PubMed ID: 27545902
[TBL] [Abstract][Full Text] [Related]
34. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
Murji A; Whitaker L; Chow TL; Sobel ML
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
[TBL] [Abstract][Full Text] [Related]
35. Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units.
Toews I; George AT; Peter JV; Kirubakaran R; Fontes LES; Ezekiel JPB; Meerpohl JJ
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD008687. PubMed ID: 29862492
[TBL] [Abstract][Full Text] [Related]
36. Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Alibhai SMH; Zukotynski K; Walker-Dilks C; Emmenegger U; Finelli A; Morgan SC; Hotte SJ; Tomlinson GA; Winquist E
Ann Intern Med; 2017 Sep; 167(5):341-350. PubMed ID: 28785760
[TBL] [Abstract][Full Text] [Related]
37. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.
Gartrell BA; Coleman RE; Fizazi K; Miller K; Saad F; Sternberg CN; Galsky MD
Eur Urol; 2014 Feb; 65(2):278-86. PubMed ID: 23706567
[TBL] [Abstract][Full Text] [Related]
38. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
